EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study

Andrea Burgalassi, Marina Romozzi iD, Giulia Vigani, Roberto De Icco, Bianca Raffaelli iD, Alberto Boccalini, Francesco De Cesaris, Paolo Calabresi, Pierangelo Geppetti, Alberto Chiarugi, Luigi Francesco Iannone iD

Cephalalgia · 2024-11 · 44 (11)

DOI: 10.1177/03331024241273968 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cephalalgia, 2024-11. Verfasst von Andrea Burgalassi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The anti-calcitonin gene-related peptide (CGRP), or its receptor (CGRP/R) monoclonal antibodies (mAbs), offer targeted, effective, and tolerated drugs for migraine. However, about 25% of patients fail to achieve a clinically meaningful response, usually leading to discontinuation. These patients often have a lengthy migraine history and multiple prior preventive treatment failures, resulting in limited therapeutic options. Herein, we describe the cause for and outcome of withdrawal of anti-CGRP/R mAb and evaluate the treatment course until discontinuation.

Methods

We conducted a prospective analysis on migraine patients attending the Florence Headache Center in Italy, who discontinued treatment with anti-CGRP/R mAbs. The primary objectives were to describe the reasons for anti-CGRP mAbs discontinuation and the treatment course. Secondary objectives were the evaluation of the absolute change from baseline in monthly headache days, response rates, persistence in medication overuse, absolute change from baseline of the overall number and days of analgesics use per month, change of MIDAS and HIT-6 at three, six, and 12 months, and the last month of treatment.

Results

Among 472 patients, 136 (28.8%) discontinued mAb treatment after an average of 9.0 ± 6.1 (mean ± SD) months. The majority (96/136, 70.6%) discontinued due to ineffectiveness, followed by lost to follow-up during treatment (18/136, 13.1%) and adverse events (10/136, 7.3%). In total, 77.9% of the 136 patients ceased treatment within the first year. Following discontinuation, 48.5% initiated new pharmacological treatment, 39.7% were lost to follow-up, and 11.8% opted not to start another treatment. The majority of patients that started a new pharmacology treatment switched to another anti-CGRP/R (46/68, 67.6%). The second most-used treatment was onabotulinumtoxinA (7/68, 10.2%; all patients in this subgroup were naïve to this treatment), followed by an anticonvulsive medication (7/68, 10.2%). The response status (≥50% reduction in monthly headache days) was achieved by 30.5%, 34.6%, and 40.0% of patients at month 3, 6, and 12 of treatment, respectively. Considering only the comprehensive last month of treatment before withdrawn the percentage of responders was 16.9%.

Conclusion

Although anti-CGRP/R mAbs have provided a substantial amelioration of migraine management, a relevant proportion of patients remains unresponsive and requires additional therapeutic support. Further research is required to identify non-responder features and address unmet needs in migraine treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, MonoclonalHumansFemaleProspective StudiesMaleMiddle AgedAdultCohort StudiesTreatment OutcomeCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAged

Stichwörter der Autor:innen

headacheineffectivenessmigraineneuropeptidenon-responderspainpreventive treatment

Substanzen

Antibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.
  • Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
  • Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.

ORCID-Profile: Marina Romozzi, Bianca Raffaelli, Luigi Francesco Iannone

Zitieren

APA

Burgalassi, A., Romozzi, M., Vigani, G., De Icco, R., Raffaelli, B., Boccalini, A., De Cesaris, F., Calabresi, P., Geppetti, P., Chiarugi, A., & Iannone, L. F. (2024). Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study. Cephalalgia. https://doi.org/10.1177/03331024241273968

Vancouver

Burgalassi A, Romozzi M, Vigani G, De Icco R, Raffaelli B, Boccalini A, et al. Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study. Cephalalgia. 2024. doi:10.1177/03331024241273968

BibTeX
@article{Burgalassi2024,
  author = {Burgalassi, Andrea and Romozzi, Marina and Vigani, Giulia and De Icco, Roberto and Raffaelli, Bianca and Boccalini, Alberto and De Cesaris, Francesco and Calabresi, Paolo and Geppetti, Pierangelo and Chiarugi, Alberto and Iannone, Luigi Francesco},
  title = {Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024241273968}
}
Kostenlos starten →